TTMCMV

Development of GMP compliant MHC/Tetramers and cell sorting procedures for Adoptive Immunotherap y against CMV Infections

TTMCMV est accrédité par Lyonbiopôle

Identity card

Global budget: 1 465 k€

Public funding: 861 k€

Public funders: ANR, Agence Nationale de la Recherche

Call for projects: ANR (ANR2007 - RIB)

Year start: 2007

Completed project (2011-02)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Human Medicines

Application fields: Infectious diseases, Oncology, Pediatrics

Technological approaches / Keywords: Biologics, Biomanufacturing, Cell therapy / Regenerative Medicine, Immunotherapy

Stage of development at the beginning of the project: Basic research

Abstract

Patients undergoing a bone marrow transplant frequently develop complications such as CMV reactivations. Cellular therapy has been demonstrated to be efficient, transfer of T cells directed against CMV being able to prevent and control viral reactivation. The objective of this project was to develop a process for manufacturing cell sorting reagent compliant with Good Manufacturing Practices and to use these reagents to set up the protocol for clinical trial. Once the manufacturing process validated through a prototype, it has been applied to produce sorting reagents for different viruses. 


Objectives

The main objectives of this project were to develop a process for manufacturing cell sorting reagent compliant with Good Manufacturing Practices (GMP), and to use these reagents to set up the therapeutic protocol for future immunotherapy clinical trial.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

The region recognized by CTL-CMV+ when cells are in contact with a CMV-infected cell is mimed to identify and capture specifically CTL-CMV+. This region is linked to magnetic beads which enable the selection of cells to be re-injected into the patient. Produced initially for research, the architecture of the sorting reagent had to be modified and the process had to be adapted. Sorting experiments resulted in a very specific sort of CTL-CMV+, thus validating the prototype. Finally, other prototypes have been produced in order to sort more CTL-CMV+, or T cells specific for other viruses.  

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte